HomeCompareSBUG vs ABBV

SBUG vs ABBV: Dividend Comparison 2026

SBUG yields 6.05% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $10.1K in total portfolio value
10 years
SBUG
SBUG
● Live price
6.05%
Share price
$33.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.8K
Annual income
$888.97
Full SBUG calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — SBUG vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSBUGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SBUG + ABBV cover 4 of 12 monthsgood coverage

Jan
ABBV
Feb
Mar
Apr
ABBV
May
Jun
Jul
ABBV
Aug
Sep
Oct
ABBV
Nov
Dec
SBUG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SBUG
Annual income on $10K today (after 15% tax)
$513.98/yr
After 10yr DRIP, annual income (after tax)
$755.62/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, ABBV beats the other by $225.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SBUG + ABBV for your $10,000?

SBUG: 50%ABBV: 50%
100% ABBV50/50100% SBUG
Portfolio after 10yr
$34.9K
Annual income
$1,021.70/yr
Blended yield
2.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SBUG
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SBUG buys
0
ABBV buys
0
No recent congressional trades found for SBUG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSBUGABBV
Forward yield6.05%3.67%
Annual dividend / share$2.00$6.20
Payout ratio50%58%
1-year div growth0%4.7%
5-year div CAGR0%8.9%
Portfolio after 10y$29.8K$39.9K
Annual income after 10y$888.97$1,154.43
Total dividends collected$7.5K$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SBUG vs ABBV ($10,000, DRIP)

YearSBUG PortfolioSBUG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,305$604.69$11,520$399.75$215.00ABBV
2$12,735$638.86$13,261$450.98$526.00ABBV
3$14,299$672.60$15,255$508.41$956.00ABBV
4$16,006$705.80$17,536$572.74$1.5KABBV
5$17,864$738.36$20,145$644.78$2.3KABBV
6$19,885$770.19$23,126$725.38$3.2KABBV
7$22,078$801.23$26,532$815.52$4.5KABBV
8$24,455$831.40$30,420$916.26$6.0KABBV
9$27,028$860.66$34,855$1,028.80$7.8KABBV
10$29,809$888.97$39,914$1,154.43$10.1KABBV

SBUG vs ABBV: Complete Analysis 2026

SBUGStock

The index is calculated on a total return basis and is intended to reflect (1) the performance of a rolling position in specified silver futures contracts that will become the first liquid nearby futures contracts three months in the future in accordance with a specified schedule and (2) the return that corresponds to the weekly announced interest rate for specified 3-month U.S. Treasury bills. The ETNs are medium-term notes that are senior unsecured debt obligations of Barclays Bank PLC.

Full SBUG Calculator →

ABBVHealthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this SBUG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SBUG vs SCHDSBUG vs JEPISBUG vs OSBUG vs KOSBUG vs MAINSBUG vs JNJSBUG vs MRKSBUG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.